NASDAQ$AGEN
Agenus Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Agenus reported first quarter 2022 financial results and provided a corporate update.
Agenus reported a revenue of $26 million for the quarter ended March 31, 2022, an increase of $14 million compared to the same quarter in 2021. The net loss for the quarter was $51 million, with per share losses of $0.19. The company ended the quarter with $263 million in cash and short-term investments.
- Prioritizing most promising clinical programs, including botensilimab combinations.
- AGEN1571 clinical trials to commence; preclinical data presented at AACR.
- Milestone payment received from Gilead for the clinical advancement of AGEN2373 targeting CD137.
- Initiated cost containment measures with expected reductions in operating expenses in coming quarters.
Headline financials
Revenue & EPS history
Agenus · Revenue · Quarterly
$25.9M
Forward guidance
Agenus has initiated cost containment measures with expected reductions in operating expenses in coming quarters.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+0.7%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+6.1%
Avg return
30 days after
49%
31 / 63 earnings
Positive
+39.9%
Q4 2011
Best reaction
-22.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -14.9% | -6.3% | — | |
| Q4 2025 | +5.8% | +19.7% | +55.8% | |
| Q3 2025 | +6.3% | +9.0% | +2.8% | |
| Q1 2025 | +20.3% | +19.6% | +77.3% | |
| Q4 2024 | -4.7% | -13.5% | -24.7% | |
| Q3 2024 | -22.3% | -30.3% | -21.0% | |
| Q2 2024 | +0.2% | -7.3% | -2.6% | |
| Q1 2024 | -11.4% | -19.0% | +27.9% | |
| Q4 2023 | -18.0% | -15.2% | -38.3% | |
| Q3 2023 | +7.5% | -16.7% | +3.8% | |
| Q2 2023 | -5.9% | -0.7% | -7.4% | |
| Q1 2023 | -3.1% | -10.7% | +28.3% | |
| Q4 2022 | +10.5% | -0.6% | -12.3% | |
| Q3 2022 | -15.5% | +5.0% | +5.0% | |
| Q2 2022 | +2.3% | +13.8% | +0.4% | |
| Q1 2022 | -0.7% | +7.2% | +7.9% | |
| Q4 2021 | +13.7% | +7.8% | -8.9% | |
| Q3 2021 | +3.6% | -7.2% | -23.2% | |
| Q2 2021 | -0.4% | +9.2% | +13.0% | |
| Q1 2021 | +4.2% | +5.1% | +36.6% | |
| Q4 2020 | -3.0% | -6.3% | -18.7% | |
| Q3 2020 | +0.0% | +4.9% | +0.5% | |
| Q2 2020 | +12.3% | +5.7% | +17.4% | |
| Q1 2020 | -4.2% | -3.0% | +45.8% | |
| Q4 2019 | -7.4% | -20.6% | -8.1% | |
| Q3 2019 | +13.3% | +25.3% | +38.2% | |
| Q2 2019 | +17.8% | +24.7% | +41.6% | |
| Q1 2019 | +7.5% | +10.2% | +1.5% | |
| Q4 2018 | -3.0% | +1.0% | -12.2% | |
| Q3 2018 | +10.1% | +5.9% | +25.0% | |
| Q2 2018 | +4.6% | +3.5% | +16.8% | |
| Q1 2018 | -14.1% | -3.3% | -14.4% | |
| Q4 2017 | +2.1% | -1.6% | -18.7% | |
| Q3 2017 | -4.4% | +1.6% | -1.4% | |
| Q2 2017 | -2.4% | -6.6% | -9.7% | |
| Q1 2017 | +10.5% | +10.5% | +2.3% | |
| Q4 2016 | +3.9% | +0.3% | -14.9% | |
| Q3 2016 | -21.8% | -26.0% | -7.1% | |
| Q2 2016 | +12.6% | +12.6% | +26.2% | |
| Q1 2016 | -16.2% | — | — | |
| Q4 2015 | +19.6% | — | — | |
| Q3 2015 | -5.4% | — | — | |
| Q2 2015 | -7.4% | — | — | |
| Q1 2015 | +17.1% | — | — | |
| Q3 2014 | -2.9% | — | — | |
| Q2 2014 | +6.2% | — | — | |
| Q1 2014 | -5.2% | — | — | |
| Q4 2013 | +0.4% | — | — | |
| Q3 2013 | +2.8% | — | — | |
| Q2 2013 | +1.0% | — | — | |
| Q1 2013 | +1.1% | — | — | |
| Q4 2012 | +4.6% | — | — | |
| Q3 2012 | -7.2% | — | — | |
| Q2 2012 | -4.2% | — | — | |
| Q1 2011 | -3.9% | — | — | |
| Q1 2012 | +6.7% | — | — | |
| Q4 2011 | +39.9% | — | — | |
| Q3 2011 | -3.7% | — | — | |
| Q2 2011 | -16.2% | — | — | |
| Q4 2010 | -4.0% | — | — | |
| Q3 2010 | -5.2% | — | — | |
| Q2 2010 | -1.2% | — | — | |
| Q1 2010 | +14.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro